Goldman Sachs
APTO

Goldman Sachs’s Aptose Biosciences, Inc. APTO Stock Holding History

Goldman Sachs’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,182
Closed -$165K – 6084
2023
Q2 		$165K Sell
1,182
-291
-20% -$60.2K ﹤0.01% 5243
2023
Q1 		$424K Sell
1,473
-8
-0.5% -$2.32K ﹤0.01% 4918
2022
Q4 		$387K Hold
1,481
– – ﹤0.01% 5003
2022
Q3 		$397K Hold
1,481
– – ﹤0.01% 5127
2022
Q2 		$495K Hold
1,481
– – ﹤0.01% 5086
2022
Q1 		$907K Hold
1,481
– – ﹤0.01% 4895
2021
Q4 		$900K Sell
1,481
-190
-11% -$179K ﹤0.01% 4936
2021
Q3 		$1.64M Buy
1,671
+185
+12% +$231K ﹤0.01% 4363
2021
Q2 		$2.22M Buy
1,486
+2
+0.1% +$4.36K ﹤0.01% 4106
2021
Q1 		$3.99M Buy
1,484
+3
+0.2% +$5.95K ﹤0.01% 3344
2020
Q4 		$2.92M Sell
1,481
-76
-5% -$179K ﹤0.01% 3443
2020
Q3 		$4.2M Buy
1,557
+54
+4% +$135K ﹤0.01% 3041
2020
Q2 		$4.27M Sell
1,503
-10
-0.7% -$32.3K ﹤0.01% 2915
2020
Q1 		$4.04M Buy
1,513
+1,450
+2,302% +$4.32M ﹤0.01% 2809
2019
Q4 		$160K Buy
+63
New +$82.1K ﹤0.01% 4949

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Goldman Sachs's APTO Position: Q3 2023 in Review

Goldman Sachs sold out of Aptose Biosciences, Inc. (APTO) in Q3 2023, closing a stake of 1,182 shares — an estimated $165K sold.

Goldman Sachs first reported a position in APTO in Q4 2019 and held it in 15 quarters. The position peaked at $4.27M in Q2 2020. 25 funds tracked by Wall St. Rank hold APTO as of Q3 2023.

  • Goldman Sachs reported no remaining Aptose Biosciences, Inc. position as of Q3 2023 after selling out during the quarter.
  • Goldman Sachs sold 1,182 Aptose Biosciences, Inc. shares in Q3 2023, an estimated $165K.
  • Goldman Sachs first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 15 quarters.
  • Goldman Sachs's Aptose Biosciences, Inc. position peaked at $4.27M in Q2 2020.
  • 25 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2023.

Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.